Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
gepotidacin, FDA and GSK
FDA set to decide on GSK's gepotidacin antibiotic in March
The FDA has started a priority review of GSK's gepotidacin, which could become the first in a new class of oral antibiotics for uncomplicated urinary tract infections (uUTIs) in over 20 years. The US regulator is scheduled to deliver a decision on the marketing application by 26th March next year, said GSK in a statement.
GSK's NDA for UTI Drug Gepotidacin Gets FDA's Priority Review
GSK plc GSK announced that the FDA has accepted its new drug application (NDA) seeking approval for its investigational, first-in-class oral antibiotic, gepotidacin for treating uncomplicated urinary tract infections (uUTIs) in female adults and adolescents.
Gepotidacin Gets Priority Review for Uncomplicated UTI in Female Patients
The FDA granted Priority Review to gepotidacin for the treatment of female adults and adolescents with uncomplicated UTI.
Gepotidacin accepted for priority review by US FDA for treatment of uncomplicated urinary tract infections in female adults and adolescents
Application supported by positive results from pivotal phase III EAGLE-2 and EAGLE-3 trials26 March 2025 assigned as action date for FDA decisionGepotidacin could be the first in a new class of oral antibiotic treatment for uUTIs in over 20 years GSK plc
GSK Plc: NDA For Gepotidacin Granted Priority Review By FDA - Quick Facts
GSK plc (GSK, GSK.L) announced the FDA has accepted the New Drug Application for gepotidacin, an oral antibiotic with a mechanism of
GSK: FDA Accepts New Drug Application for Gepotidacin
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing opportunities, strengthen advisor-client relationships and build investor experiences. Learn More.
US FDA accepts for priority review GSK’s NDA for gepotidacin to treat uncomplicated urinary tract infections in female adults and adolescents
US FDA accepts for priority review GSK’s NDA for gepotidacin to treat uncomplicated urinary tract infections in female adults and adolescents: London, UK Thursday, October 17, 2
4d
GSK Seeks FDA Approval For Oral Antibiotic For Urinary Tract Infections, Probably First In New Class In Over 20 Years
GSK's gepotidacin, an oral antibiotic for uUTIs, could be the first in over 20 years. The FDA granted Priority Review with a ...
PharmiWeb
6d
GSK and ViiV Healthcare to showcase advances across industry-leading infectious disease portfolio at IDWeek 2024
New data to be shared on GSK’s RSV vaccine across different age groups of patients at increased risk • Efficacy data for gepotidacin in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Advance to World Series
Reaches tentative union deal
Boat rider arrested in FL
Postpones US tour
Baldwin returns to 'SNL'
MS after game shooting
Opens up on Russian camp
Trump's Pennsylvania rally
New Mexico flash flooding
Philip Zimbardo dies at 91
NYC Halloween dog parade
Ferry dock collapses in GA
US probing documents leak
Rock & Roll HOF '24 class
Opioid suits settlement deal
Orionids meteor shower
US deficit reaches $1.8T
Antitrust ruling delayed
Urges support for Ukraine
Launches OneWeb mission
Challenges military listing
CVS workers strike
Bladder cancer drug pulled
Ex-MN congressman dies
G7 ministers back Ukraine
Georgia beats Texas
ISR strikes northern Gaza
Probes near miss in Austin
Oakland fire burns homes
Frozen waffles recalled
Related topics
GSK
GlaxoSmithKline
New drug application
Feedback